Pioglitazone

Hmm… We’d better think about this again. Pioglitazone is not a good first‑line choice because it causes weight gain and fluid retention and it lacks clear cardiovascular outcome benefits. If a thiazolidinedione is considered at all, it is considered in cases where first line drugs are not indicated or unavailable, or in combination with other first line drugs.

Try to think about other drugs with favourable weight and cardiovascular profiles. Always consider the full clinical context when prescribing medications and try again!

  • Presentation
End Session and View Feedback
  • Costas and his father discuss and spend time together. [undo]
  • [undo]
  • Increased secretion of insulin from the pancreas [undo]
  • ΜΕΤΑΒΟΛΙΣΜΟΣ ΤΩΝ ΚΥΤΤΑΡΙΚΩΝ ΕΝΖΥΜΩΝ (PH/ΘΕΡΜΟΚΡΑΣΙΑ) [undo]
  • new node [undo]
  • Pioglitazone [undo]

Map: Michael Green_GEMD_2 (1116)
Node: 21115
Score:

reset

OpenLabyrinth
OpenLabyrinth is an open source educational pathway system

Review your pathway

  • Insulin
  • Costas and his father discuss and spend time together.
  • Increased secretion of insulin from the pancreas
  • ΜΕΤΑΒΟΛΙΣΜΟΣ ΤΩΝ ΚΥΤΤΑΡΙΚΩΝ ΕΝΖΥΜΩΝ (PH/ΘΕΡΜΟΚΡΑΣΙΑ)
  • new node
  • Pioglitazone

Reminder

empty_reminder_msg

FINISH

Time is up